NEWS RELEASE
ID Specialist Input Improves Outcomes for Outpatient Parenteral Antimicrobial Therapy: New IDSA Guidelines
AT A GLANCE
|
ARLINGTON, Va. – Before patients receive intravenous (IV) antimicrobial infusion therapy outside of the hospital – whether at home, a doctor’s office or a skilled nursing facility – an infectious diseases (ID) specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America (IDSA). Once they begin receiving outpatient parenteral antimicrobial therapy (OPAT), patients should be monitored regularly, note the guidelines, which are being published in the journal Clinical Infectious Diseases.
OPAT has long been the standard of care to treat an infection that requires IV antimicrobials because it is less expensive than hospital-based treatment and is preferred by most patients. Since the previous guidelines were published in 2004, three large studies have found this strategy to be safe: there is no difference in the number of adverse events related to OPAT compared to hospital-administered IV antimicrobial therapy.
Additionally, new research underscores the value of review by an ID physician, nurse or pharmacist before starting OPAT, noting that it is associated with a lower risk of hospital readmission. In many cases the ID specialist will recommend an oral instead of an IV antimicrobial. Studies show up to 39 percent of OPAT patients can be switched from IV to oral antimicrobials and also note that as many as 1 in 10 patients don’t need an antimicrobial at all. One study found an ID specialist-led stewardship program reduced pediatric OPAT orders by 24 percent, without increasing readmissions.
“The majority of patients referred for OPAT therapy do need it, but in many cases an oral antimicrobial would do the job. Given the growing worldwide problem with antimicrobial overuse and resistance, any opportunity to de-escalate these drugs is critically important,” said Anne H. Norris, MD, guidelines co-chair and associate professor of clinical medicine at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia. “Not only does this provide good stewardship of antimicrobials, but lowers costs and potentially improves patients’ well-being. It’s always better to avoid IV access if possible, and the narrower spectrum oral antimicrobials kill off fewer healthy bacteria than broader spectrum agents.”
Newer research also suggests patients should have regular blood tests while receiving OPAT to monitor for toxicity and ensure the drug levels are adequate. Although there is no definitive evidence regarding how often that should occur, most patients are tested weekly, said Dr. Norris.
Other new recommendations in the guideline include:
- OPAT vancomycin should be monitored closely throughout the course of treatment for adverse events as one study found 42 percent of patients developed nephrotoxicity (kidney damage) after 14 days on therapy. If nephrotoxicity develops, options include lowering the dose or stopping the vancomycin and switching to another medication such as daptomycin.
- In patients with no history of allergy to antimicrobials in the same class, the first dose of a new IV antimicrobial may be given at home under the supervision of a health care worker who is trained to manage an allergic reaction.
- In patients receiving OPAT antimicrobials for two weeks or less, it is acceptable to deliver the medication using a midline catheter in the arm rather than via a peripherally inserted central catheter (PICC) or central venous catheter.
- If a patient with a PICC develops a blood clot, it is not necessary to remove and replace the catheter if anticoagulation is started, the catheter is well-positioned and arm pain and swelling have decreased.
In addition to Dr. Norris, the guidelines panel includes co-chair Nabin K. Shrestha, MD, MPH, FIDSA; Genève M. Allison, MD, MS, Sara C. Keller, MD, MPH, MSHP; Kavita P. Bhavan, MD, MHS, FIDSA; John J. Zurlo, MD; Adam L. Hersh, MD, PhD; Lisa A. Gorski, MS; John A. Bosso, PharmD, FIDSA; Mobeen H. Rathore, MD, FIDSA; Antonio Arrieta, MD, FIDSA; Russell M. Petrak, MD, FIDSA; Akshay Shah, MD, FIDSA; Richard B. Brown, MD, FIDSA; Shandra L. Knight, MS and Craig A. Umscheid, MD.
IDSA has published more than 50 treatment guidelines on various conditions and infections, ranging from HIV/AIDS to skin and soft tissue infections. As with other IDSA guidelines, the OPAT guidelines will be available in a smartphone format and a pocket-sized quick-reference edition. The full guidelines are available free on the IDSA website at https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy745/5175018.
Note: For a copy of the OPAT guidelines released Nov. 13, 2018, please contact Lauren Martin at (312) 558-1770 or lmartin@pcipr.com.
# # #
The Infectious Diseases Society of America (IDSA), based in Arlington, Va., is a professional society representing more than 11,000 physicians and scientists who specialize in infectious diseases. For more information, visit www.idsociety.org. Follow IDSA on Facebook and Twitter.
Clinical Infectious Diseases is a leading journal in the field of infectious diseases with a broad international readership. The journal publishes articles on a variety of subjects of interest to practitioners and researchers. Topics range from clinical descriptions of infections, public health, microbiology, and immunology to the prevention of infection, the evaluation of current and novel treatments, and the promotion of optimal practices for diagnosis and treatment. The journal publishes original research, editorial commentaries, review articles, and practice guidelines and is among the most highly cited journals in the field of infectious diseases. Clinical Infectious Diseases is an official publication of the Infectious Diseases Society of America (IDSA).